Anika Therapeutics, Inc. — Form 10-Q
Filed July 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Stephen Griffin, President and CEO of Anika Therapeutics, certified the Q2 2026 10-Q filing (period ended June 30, 2026) on July 29, 2026, attesting that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Standard periodic SOX certification; routine attestation with no unusual findings, changes, or exceptions disclosed.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.